New drug combo aims to tame rare liver virus

NCT ID NCT05461170

Ongoing Disease control Sponsor: Vir Biotechnology, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests two experimental drugs, Elebsiran and Tobevibart, in 95 adults with chronic hepatitis D, a serious liver infection. Participants receive the drugs as injections along with a standard oral antiviral. The goal is to see if the combination can lower virus levels and improve liver health. The study is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Elebsiran (VIR-2218) and Tobevibart (VIR-3434) injections, plus oral NRTI
What this could lead to: If successful, this could lead to a new treatment option that controls hepatitis D virus and reduces liver damage, potentially preventing long-term complications.
What could go wrong: This is an early-phase trial with only 95 people, so results may not apply to everyone. The drugs may not work as hoped, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis hepatitis D virus infection Hepatitis D, Chronic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS D, CHRONIC

Contacts and locations

Show contact details

Locations

Investigative Site

Sofia, 1407, Bulgaria
Investigative Site

Sofia, 1431, Bulgaria
Investigative Site

Stara Zagora, 6003, Bulgaria
Investigative Site

Clichy, 92110, France
Investigative Site

Pessac, 33600, France
Investigative Site

Rennes, 35000, France
Investigative Site

Toulouse, 31000, France
Investigative Site

Frankfurt, 60596, Germany
Investigative Site

Hanover, 30625, Germany
Investigative Site

Tübingen, 72076, Germany
Investigative Site

Milan, 20122, Italy
Investigative Site

Pisa, 56124, Italy
Investigative Site

Chisinau, MD-2025, Moldova
Investigative Site

Rotterdam, 3015 GD, Netherlands
Investigative Site

Auckland, 1010, New Zealand
Investigative Site

Bucharest, 021105, Romania
Investigative Site

Birmingham, B15 2TT, United Kingdom
Investigative Site

London, E1 1RF, United Kingdom
Investigative Site

London, SE5 9RS, United Kingdom
Investigative Site

Manchester, M8 5RB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.